Mirum Pharmaceuticals ( (MIRM) ) has released its Q2 earnings. Here is a breakdown of the information Mirum Pharmaceuticals presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases affecting both children and adults, with a portfolio that includes three approved medications targeting rare liver and genetic disorders.
In its second quarter of 2025 earnings report, Mirum Pharmaceuticals announced a total revenue of $128 million, reflecting robust growth and prompting an increase in its annual revenue guidance to between $490 million and $510 million. The company highlighted strong performance from its international business and the U.S. launch of its PFIC treatment, Livmarli.
Key financial metrics from the report include global net product sales of $127.8 million, with Livmarli sales alone contributing $88.2 million, marking an 87% increase from the previous year. Additionally, Bile Acid Medicines sales grew by 30% compared to the same quarter in 2024. Mirum also reported a solid balance sheet with $321.7 million in cash, cash equivalents, and investments.
Strategically, Mirum is advancing its pipeline with several significant milestones anticipated in 2026, including the completion of the VISTAS study for volixibat in primary sclerosing cholangitis and the EXPAND Phase 3 study for Livmarli. The company also plans to initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome by the end of 2025.
Looking ahead, Mirum Pharmaceuticals remains optimistic about its growth trajectory, supported by its strong commercial performance and a promising pipeline that is poised to achieve several late-stage clinical milestones in the coming years.